Homburger has advised Siegfried on the acquisition of two Novartis manufacturing sites in Spain

IFLR is part of Legal Benchmarking Limited, 1-2 Paris Garden, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement


Homburger has advised Siegfried on the acquisition of two Novartis manufacturing sites in Spain

Sponsored by

21Homburger_f86a79.png

Homburger has advised Siegfried on the acquisition of two Novartis manufacturing sites in Spain

Homburger AG

Prime Tower

Hardstrasse 201

CH–8005 Zurich

T +41 43 222 10 00

F +41 43 222 15 00

lawyers@homburger.ch

 

 

On September 29, 2020, Siegfried Holding AG (SWX: SFZN) announced that it has entered into a purchase agreement with Novartis AG (SWX: NOVN) regarding the acquisition of the pharmaceutical manufacturing sites in El Masnou and Barberà des Vallès (both Barcelona province, Spain). The parties did not disclose the purchase price.

As part of the transaction, Novartis and Siegfried have entered into various agreements regarding their cooperation during the carve-out and integration phase and providing for multi-year purchase commitments for the manufacturing and supply of relevant Novartis products. Subject to customary closing conditions and the necessary regulatory approvals, the transaction is expected to close at the end of 2020.

Homburger has acted as Swiss counsel to Siegfried in this transaction. The Homburger team was led by associate Marc Hanslin (Corporate | M&A) and included associates Jeremy Reichlin (Data Protection | Privacy) and Kirsten Schmidt (IP | IT and Data Protection | Privacy).

Contact

Katharina Hoheneck | Marketing | marketing@homburger.ch

Gift this article